Peter W Janes

8PUBLICATIONS
55CO-AUTHORS
Haematological tumoursMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 10, 2026
A Phase 1 and Biodistribution study of Ifabotuzumab, a humanized agonistic EphA3-targeted antibody, in patients with recurrent glioblastoma.

|Nov 13, 2025
ADAM10 Knockout from Human Glioblastoma and Colon Cancer Cells Modulates Diverse Signalling Networks and Inhibits Tumour Growth In Vivo.

Hengkang Yan, Sakshi Arora, Linda Hii

|May 13, 2025
Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2.

Sagun Parakh, Nhi Huynh, Diana Dong Cao

|May 25, 2024
An Anti-VEGF-B Antibody Reduces Abnormal Tumor Vasculature and Enhances the Effects of Chemotherapy.

Peter W Janes, Adam C Parslow, Diana Cao

|Sep 28, 2023
Inhibition of EphA3 Expression in Tumour Stromal Cells Suppresses Tumour Growth and Progression.

Mary E Vail, Rae H Farnsworth, Linda Hii

|Feb 25, 2023
Eph Receptors in Cancer.

Sakshi Arora, Andrew M Scott, Peter W Janes

Pageof 2

Frequent Collaborators

3 joint publications

Sakshi Arora

2 joint publications

Nancy Yanan Guo

2 joint publications

Andrew M Scott

2 joint publications

Christian W Wichmann